Categories:

• Agriculture and Forestry
• Automotive
• Biotechnology and Pharmaceuticals
• Chemicals
• Construction and Maintenance
• Consumer Goods and Services
• Electronics and Electrical
• Energy and Environment
• Food and Related Products
• Industrial Goods and Services
• Information Technology
• Materials
• Real Estate
• Telecommunications
• Textiles and Nonwovens
• Transportation and Logistics

Popular Tags:

• player
• mp4
• mp4 player
• screen
• player screen
• screen mp4
• 4gb
• player 4gb
• 4gb mp4
• card
• slot
• player card
• 18inch
• inch
• 15inch
• inch mp4
• inch player
• flash
• style
• builtin

Home › First Self-Injectable HIV Antibody: 98% Success Rate In Phase 2b Clinical Trial, Could Be Commercial In 2017

 

First Self-Injectable HIV Antibody: 98% Success Rate In Phase 2b Clinical Trial, Could Be Commercial In 2017

2015-08-19 07:01:19| drugdiscoveryonline Home Page

The first self-injectable antibody, PRO 140, has documented an impressive 98% success rate in a Phase 2b clinical trial for patients with HIV. In a monotherapy study, some HIV patients using PRO 140 are experiencing a completely suppressed viral load for 11 months.

Tags: in rate commercial trial

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»

26.04 Dead whistleblower accused Boeing of safety breaches 26.04 Introducing Mens Hybrid Skincare Brand Enhanse 26.04 Washington Corner April 2024 26.04 Does history repeat itself? 26.04 FDA finalizes guidance to provide further clarity on Veterinary Feed Directives 26.04 Post Office paid widow in instalments for silence 26.04 NCBA statement on USDA final traceability rule 26.04 Kimberly-Clark, Amcor Develop 30% Recycled Content Packaging More »